Multi‐level metabolic engineering of Escherichia coli for high‐titer biosynthesis of 2′‐fucosyllactose and 3‐fucosyllactose [PDF]
Microbial Biotechnology, 2022 Fucosyllactoses (FL), including 2′‐fucosyllactose (2′‐FL) and 3‐fucosyllactose (3‐FL), have garnered considerable interest for their value in newborn formula and pharmaceuticals.
Mengli Li +5 more
doaj +5 more sources
Safety of 3‐FL (3‐Fucosyllactose) as a novel food pursuant to Regulation (EU) 2015/2283 [PDF]
EFSA Journal, 2021 Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3‐fucosyllactose (3‐FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) +26 more
doaj +11 more sources
Safety of 3‐fucosyllactose (3‐FL) produced by a derivative strain of Escherichia coli K‐12 DH1 as a novel food pursuant to Regulation (EU) 2015/2283 [PDF]
EFSA Journal, 2023 Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3‐fucosyllactose (3‐FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) +29 more
doaj +2 more sources
Safety of 3‐fucosyllactose (3‐FL) produced by a derivative strain of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283 [PDF]
EFSA Journal, 2022 Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3‐fucosyllactose (3‐FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) +27 more
doaj +2 more sources
Regulation of hBD-2, hBD-3, hCAP18/LL37, and Proinflammatory Cytokine Secretion by Human Milk Oligosaccharides in an Organotypic Oral Mucosal Model [PDF]
Pathogens, 2021 Human milk oligosaccharides (HMOs), the third largest solid fraction in human milk, can modulate inflammation through Toll-like receptor signaling, but little is known about their immunomodulatory potential in the oral cavity.
Ulvi K. Gürsoy +5 more
doaj +3 more sources
Microorganisms, 2023 Human milk oligosaccharides (HMOs) shape the developing infant gut microbiota. In this study, a semi-continuous colon simulator was used to evaluate the effect of 2 HMOs—2′-fucosyllactose (2′-FL) and 3-fucosyllactose (3-FL)—on the composition of infant ...
Krista Salli +7 more
doaj +1 more source
Molecules, 2022 Human milk is an intricate, bioactive food promoting infant health. We studied the composition of human milk samples collected over an 8-month lactation using 1H NMR metabolomics.
Maaria Kortesniemi +3 more
doaj +1 more source
Differences in the content of human milk oligosaccharides between foremilk and hind milk
Food Bioengineering, 2023 Human milk oligosaccharides (HMOs) are the second largest carbohydrate component and the third largest nutrient after lactose, and their content and composition are related to the genetic characteristics of the mother, lactation period, geography, and ...
Zhiping Pu +6 more
doaj +1 more source
Frontiers in Microbiology, 2020 Human milk oligosaccharides (hMOs) are important bioactive components in mother’s milk contributing to infant health by supporting colonization and growth of gut microbes.
Lianghui Cheng +8 more
doaj +1 more source
Frontiers in Bioengineering and Biotechnology, 2020 Recombinant whole-cell biocatalysts are widely used for biotransformation of valuable products. However, some key enzymes involved in biotransformation processes are unstable and cannot be easily expressed in the functional form.
Yunjeong Park +15 more
doaj +1 more source